JAK Inhibitor News and Research

RSS
Pfizer reports positive results from two tofacitinib Phase 3 trials for moderate-to-severe plaque psoriasis

Pfizer reports positive results from two tofacitinib Phase 3 trials for moderate-to-severe plaque psoriasis

FDA approves sNDA to include radiographic data updating label of Pfizer XELJANZ for treatment of RA

FDA approves sNDA to include radiographic data updating label of Pfizer XELJANZ for treatment of RA

Pfizer reports positive results from two tofacitinib Phase 3 trials for chronic plaque psoriasis

Pfizer reports positive results from two tofacitinib Phase 3 trials for chronic plaque psoriasis

Tofacitinib improves disease activity and inhibits progression of joint damage in RA patients

Tofacitinib improves disease activity and inhibits progression of joint damage in RA patients

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Pfizer announces that 14 abstracts for tofacitinib to be presented at ACR/ARHP annual meeting

Pfizer announces that 14 abstracts for tofacitinib to be presented at ACR/ARHP annual meeting

FDA extends action date for Pfizer’s tofacitinib NDA review

FDA extends action date for Pfizer’s tofacitinib NDA review

Tofacitinib efficacy suggested for rheumatoid arthritis

Tofacitinib efficacy suggested for rheumatoid arthritis

Top-line results from Pfizer's tofacitinib Phase 3 study on moderate-to-severe active RA

Top-line results from Pfizer's tofacitinib Phase 3 study on moderate-to-severe active RA

AstraZeneca, Rigel enter global license agreement for R256 inhaled JAK inhibitor to treat chronic asthma

AstraZeneca, Rigel enter global license agreement for R256 inhaled JAK inhibitor to treat chronic asthma

Patients with NK/T-cell lymphomas might benefit from treatment with JAK inhibitors

Patients with NK/T-cell lymphomas might benefit from treatment with JAK inhibitors

Incyte, Lilly announce 12-week results from baricitinib Phase IIb study on RA

Incyte, Lilly announce 12-week results from baricitinib Phase IIb study on RA

FDA AAC recommends approval of Pfizer’s tofacitinib for RA

FDA AAC recommends approval of Pfizer’s tofacitinib for RA

FDA accepts Pfizer's tofacitinib NDA for review

FDA accepts Pfizer's tofacitinib NDA for review

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

EMA validates Pfizer's Market Authorisation Application for tofacitinib to treat rheumatoid arthritis

EMA validates Pfizer's Market Authorisation Application for tofacitinib to treat rheumatoid arthritis

Incyte receives FDA approval for Jakafi to treat intermediate or high-risk MF

Incyte receives FDA approval for Jakafi to treat intermediate or high-risk MF

YM BioSciences reports preclinical results of CYT387 in multiple myeloma

YM BioSciences reports preclinical results of CYT387 in multiple myeloma

Incyte announces additional results from ruxolitinib Phase III trial on myelofibrosis

Incyte announces additional results from ruxolitinib Phase III trial on myelofibrosis

Incyte seeks FDA marketing approval of ruxolitinib for myelofibrosis

Incyte seeks FDA marketing approval of ruxolitinib for myelofibrosis